|
1
|
Nduka OO and Parrillo JE: The
pathophysiology of septic shock. Crit Care Clin. 25:677–702. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cinel I and Opal SM: Molecular biology of
inflammation and sepsis: a primer. Crit Care Med. 37:291–304. 2009.
View Article : Google Scholar
|
|
3
|
Dellinger RP, Levy MM, Carlet JM, et al:
Surviving sepsis campaign: international guidelines for management
of severe sepsis and septic shock: 2008. Intensive Care Med.
34:17–60. 2008. View Article : Google Scholar :
|
|
4
|
Neyrinck AP, Liu KD, Howard JP and Matthay
MA: Protective mechanisms of activated protein C in severe
inflammatory disorders. Br J Pharmacol. 158:1034–1047. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ranieri VM, Thompson BT, Barie PS, et al:
PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults
with septic shock. N Engl J Med. 366:2055–2064. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parrish WR, Gallowitsch-Puerta M, Czura CJ
and Tracey KJ: Experimental therapeutic strategies for severe
sepsis: mediators and mechanisms. Ann NY Acad Sci. 1144:210–236.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Michalik L and Wahli W: Involvement of
PPAR nuclear receptors in tissue injury and wound repair. J Clin
Invest. 116:598–606. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Delayre-Orthez C, Becker J, Guenon I,
Lagente V, Auwerx J, Frossard N and Pons F: PPARalpha downregulates
airway inflammation induced by lipopolysaccharide in the mouse.
Respir Res. 6:912005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL
and Li YJ: Fenofibrate decreases asymmetric dimethylarginine level
in cultured endothelial cells by inhibiting NF-kappaB activity.
Naunyn Schmiedebergs Arch Pharmacol. 371:401–407. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zambon A, Gervois P, Pauletto P, Fruchart
JC and Staels B: Modulation of hepatic inflammatory risk markers of
cardiovascular diseases by PPAR-alpha activators: clinical and
experimental evidence. Arterioscler Thromb Vasc Biol. 26:977–986.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ozansoy G, Akin B, Aktan F and Karasu C:
Short-term gemfibrozil treatment reverses lipid profile and
peroxidation but does not alter blood glucose and tissue
antioxidant enzymes in chronically diabetic rats. Mol Cell Biochem.
216:59–63. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roy A and Pahan K: Gemfibrozil, stretching
arms beyond lipid lowering. Immunopharmacol Immunotoxicol.
31:339–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dasgupta S, Roy A, Jana M, Hartley DM and
Pahan K: Gemfibrozil ameliorates relapsing-remitting experimental
autoimmune encephalomyelitis independent of peroxisome
proliferator-activated receptor-alpha. Mol Pharmacol. 72:934–946.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sivarajah A, Chatterjee PK, Hattori Y, et
al: Agonists of peroxisome-proliferator activated receptor-alpha
(clofibrate and WY14643) reduce renal ischemia/reperfusion injury
in the rat. Med Sci Monit. 8:BR532–BR539. 2002.PubMed/NCBI
|
|
15
|
Nanji AA, Dannenberg AJ, Jokelainen K and
Bass NM: Alcoholic liver injury in the rat is associated with
reduced expression of peroxisome proliferator-alpha
(PPARalpha)-regulated genes and is ameliorated by PPARalpha
activation. J Pharmacol Exp Ther. 310:417–424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hubbard WJ, Choudhry M, Schwacha MG, Kerby
JD, Rue LW III, Bland KI and Chaudry IH: Cecal ligation and
puncture. Shock. 24(Suppl 1): 52–57. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu WT, Lee CC, Lee CJ, Subeq YM, Lee RP
and Hsu BG: Rosiglitazone ameliorates endotoxin-induced organ
damage in conscious rats. Biol Res Nurs. 13:38–43. 2011. View Article : Google Scholar
|
|
18
|
Standage SW, Caldwell CC, Zingarelli B and
Wong HR: Reduced peroxisome proliferator-activated receptor α
expression is associated with decreased survival and increased
tissue bacterial load in sepsis. Shock. 37:164–169. 2012.
View Article : Google Scholar :
|
|
19
|
Wiel E, Lebuffe G, Robin E, et al:
Pretreatment with peroxysome proliferator-activated receptor alpha
agonist fenofibrate protects endothelium in rabbit Escherichia coli
endotoxin-induced shock. Intensive Care Med. 31:1269–1279. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jozefowicz E, Brisson H, Rozenberg S, et
al: Activation of peroxisome proliferator-activated receptor-alpha
by fenofibrate prevents myocardial dysfunction during endotoxemia
in rats. Crit Care Med. 35:856–863. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hill MR, Clarke S, Rodgers K, Thornhill B,
Peters JM, Gonzalez FJ and Gimble JM: Effect of peroxisome
proliferator-activated receptor alpha activators on tumor necrosis
factor expression in mice during endotoxemia. Infect Immun.
67:3488–3493. 1999.PubMed/NCBI
|
|
22
|
van der Poll T and van Deventer SJ:
Cytokines and anticytokines in the pathogenesis of sepsis. Infect
Dis Clin North Am. 13:413–426. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu J, Chavis JA, Racke MK and Drew PD:
Peroxisome proliferator-activated receptor-alpha and retinoid X
receptor agonists inhibit inflammatory responses of astrocytes. J
Neuroimmunol. 176:95–105. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takano H, Nagai T, Asakawa M, et al:
Peroxisome proliferator-activated receptor activators inhibit
lipopolysaccharide-induced tumor necrosis factor-alpha expression
in neonatal rat cardiac myocytes. Circ Res. 87:596–602. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rosenson RS: Effect of fenofibrate on
adiponectin and inflammatory biomarkers in metabolic syndrome
patients. Obesity (Silver Spring). 17:504–509. 2009. View Article : Google Scholar
|
|
26
|
Zhao SP, Ye HJ, Zhou HN, Nie S and Li QZ:
Gemfibrozil reduces release of tumor necrosis factor-alpha in
peripheral blood mononuclear cells from healthy subjects and
patients with coronary heart disease. Clin Chim Acta. 332:61–67.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng SM, Chu KM and Lai JH: The
modulatory mechanisms of fenofibrate on human primary T cells. Eur
J Pharm Sci. 40:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stienstra R, Mandard S, Tan NS, et al: The
interleukin-1 receptor antagonist is a direct target gene of
PPARalpha in liver. J Hepatol. 46:869–877. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu SF and Malik AB: NF-kappaB activation
as a pathological mechanism of septic shock and inflammation. Am J
Physiol Lung Cell Mol Physiol. 290:L622–L645. 2006. View Article : Google Scholar
|
|
30
|
Delerive P, Gervois P, Fruchart JC and
Staels B: Induction of IkappaB alpha expression as a mechanism
contributing to the anti-inflammatory activities of peroxisome
proliferator-activated receptor-alpha activators. J Biol Chem.
275:36703–36707. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ji Y, Wang Z, Li Z and Liu J: Modulation
of LPS-mediated inflammation by fenofibrate via the TRIF-dependent
TLR4 signaling pathway in vascular smooth muscle cells. Cell
Physiol Biochem. 25:631–640. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Galley HF: Oxidative stress and
mitochondrial dysfunction in sepsis. Br J Anaesth. 107:57–64. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maitra U, Chang S, Singh N and Li L:
Molecular mechanism underlying the suppression of lipid oxidation
during endotoxemia. Mol Immunol. 47:420–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Victor VM and De la Fuente M: Immune cells
redox state from mice with endotoxin-induced oxidative stress.
Involvement of NF-kappaB. Free Radic Res. 37:19–27. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Koksal GM, Sayilgan C, Aydin S, Oz H and
Uzun H: Correlation of plasma and tissue oxidative stresses in
intra-abdominal sepsis. J Surg Res. 122:180–183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olukman M, Sezer ED, Ulker S, Sözmen EY
and Cınar GM: Fenofibrate treatment enhances antioxidant status and
attenuates endothelial dysfunction in streptozotocin-induced
diabetic rats. Exp Diabetes Res. 2010:8285312010. View Article : Google Scholar
|
|
37
|
Boshra V and Moustafa AM: Effect of
preischemic treatment with fenofibrate, a peroxisome
proliferator-activated receptor-α ligand, on hepatic
ischemia-reperfusion injury in rats. J Mol Histol. 42:113–122.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lorente JA and Marshall JC: Neutralization
of tumor necrosis factor in preclinical models of sepsis. Shock.
24(Suppl 1): 107–119. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Szakmany T, Hauser B and Radermacher P:
N-acetylcysteine for sepsis and systemic inflammatory response in
adults. Cochrane Database Syst Rev. 9:CD0066162012.PubMed/NCBI
|
|
40
|
Mermis JD and Simpson SQ: HMG-CoA
reductase inhibitors for prevention and treatment of severe sepsis.
Curr Infect Dis Rep. 14:484–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
